If 4 consists of FDA approval; PIII; partnership, then I get out. Those are the main 3 things right now in YM's pipeline to make it bounce(amongst other smaller things). Undoubtedly there will be more things in the future such as new drugs, marketing, etc. But those will be more so years than <1yr. I see plenty of other company opportunities that can bounce sooner, which is why I do love YMI, but I'm in stocks to make money like most of you.
If it gets to 4 before any of those three things hit, then all the better and I'll stay in longer. Looks like so far the 5 million share buy wasn't an institution, then again it may be too early for a SEC filing? But I see no new filings, last one was late March.
Realistically as well, Nimo is not a well marketed drug, but their JAK inhibitor/CYT is. Remember too that even after FDA, these things can take 3-4 years to get moving. YM is still an early stage company, which is doing pretty well regardless. I'm fairly certain that regardless of your short/medium/long position, anyone should do fine in YM.
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM